Unemployment, work hour reduction, and income loss: An international, multicentered, cross-sectional study of neuromyelitis optica spectrum disorder
- PMID: 40629959
- PMCID: PMC12501392
- DOI: 10.1177/13524585251349139
Unemployment, work hour reduction, and income loss: An international, multicentered, cross-sectional study of neuromyelitis optica spectrum disorder
Abstract
Objectives: To assess loss of employment, work hours, and wages of people with aquaporin-4 antibody-positive or double-seronegative/antibody status unknown neuromyelitis optica spectrum disorder (NMOSD) internationally.
Methods: An investigator-designed survey was administered to adults ages 18-70 years with NMOSD and distributed by neurologists in 23 countries, July 2022 to September 2023.
Results: There were 897 participants (635 aquaporin-4 antibody positive, 262 double-seronegative/untested; 81.4% female, average age 42.5 years, average disease duration 7.6 years, median 2 disease attacks since diagnosis). NMOSD impact was visual loss (34.0% unilateral; 28.2% bilateral), 61.8% with spinal cord disease, 55.6% with pain, 43.6% with fatigue, 38.2% with depressed mood, and 25.0% with gait aid use. In total, 92.6% took immunosuppressive therapy. Employment rates were 62.6% before and 36.3% after NMOSD diagnosis. In a multivariable model, statistically significant independent associations with unemployment in NMOSD were older age (odds ratio (OR) = 0.97, p < 0.001), being female (OR = 0.48, p < 0.001), bilateral visual loss (OR = 0.61, p = 0.02), highest frequency of depressed mood (OR = 0.29, p < 0.001), and walking aid use (OR = 0.38, p < 0.001).
Discussion: Approximately 1/3 of people living with NMOSD of potential working age are in the workforce. Unemployment in NMOSD is associated with previously recognized factors but also self-reported low mood, gait aid use, and bilateral visual loss.
Keywords: Employment; income; neurology; neuromyelitis optica; outcomes; socioeconomic factors.
Conflict of interest statement
Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr F.J.M. has received research funding for her institution from Alexion, Amgen, EMD Serono, Genentech, Novartis, and TG Therapeutics and consulting fees from Alexion, EMD Serono, Genentech, and Roche. Dr T.Y. has received honoraria from ASNA, Edanz Pharma, Euroimmun AG, Merck, Novartis, Roche, Terumo BCT for consulting services and speaker’s fees, and research grants from the National Medical Research Council (NMRC Singapore) and Roche. Dr A.S. has received research grants from The Turkish Multiple Sclerosis Society and research grants from The Scientific and Technological Research Council of Turkey & Istanbul University-Cerrahpasa Research Support Funds. Dr A.C.-C. has received a grant from the Instituto de Salud Carlos III, Spain; JR19/00007.
Figures
References
-
- World Bank Blogs. New World Bank country classifications by income level: 2021-2022, https://blogs.worldbank.org/en/opendata/new-world-bank-country-classific... (accessed 20 June 2024).
-
- World Bank Gender Data Portal. Labor force participation rate (% of population), https://genderdata.worldbank.org/en/indicator/sl-tlf-acti-zs (accessed 23 May 2024).
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources